Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback